DY
DYAI.US Dyadic International Inc
- Market cap
- USD 13.1M
- P/E
- -
- P/B
- 11.03x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is DYAI.US undervalued?
Graham numberThe Graham number of Dyadic International Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dyadic International Inc fundamental analysis
No fundamental analysis for Dyadic International Inc yet.
Dyadic International Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dyadic International Inc
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fung…
Full company profileDyadic International Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dyadic International Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 593K | 758K | 1.30M | 1.68M | 1.60M | 2.40M | 2.93M | 2.90M | 3.50M | 1.23M | 3.36M |
| Gross Profit | 76.7K | 78.2K | 268K | 221K | 177K | 459K | 807K | 923K | 2.30M | -1.09M | 848K |
| Operating Income | -5.96M | -7.13M | -7.59M | -9.28M | -10.0M | -14.7M | -10.2M | -8.23M | -5.90M | -7.15M | -7.71M |
| EBITDA | -5.32M | -2.20M | -168K | -9.23M | -9.96M | -11.1M | -10.1M | -8.15M | -5.38M | -6.86M | -7.56M |
| Net Income | -3.61M | -2.14M | -5.69M | -8.31M | -9.33M | -13.1M | -9.74M | -6.80M | -5.81M | -7.36M | -7.25M |
| EPS | -0.10 | -0.07 | -0.21 | -0.31 | -0.34 | -0.47 | -0.34 | -0.24 | -0.20 | -0.23 | -0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 58.7M | 50.7M | 43.3M | 37.5M | 30.1M | 21.3M | 13.7M | 8.22M | 9.93M | 9.95M | 7.93M |
| Total Liabilities | 1.01M | 769K | 850K | 1.59M | 1.63M | 2.91M | 2.63M | 2.34M | 7.46M | 8.71M | 10.5M |
| Shareholders' Equity | 57.7M | 50.0M | 42.5M | 35.9M | 28.4M | 18.4M | 11.1M | 5.88M | 2.47M | 1.23M | -2.58M |
| Cash & Short-term Investments | 48.9M | 47.7M | 41.2M | 34.2M | 29.1M | 20.3M | 12.6M | 7.26M | 9.26M | 7.32M | 4.57M |
| Total Debt | - | - | - | - | - | - | - | 137K | 5.07M | 5.06M | 5.10M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.04M | -2.61M | -4.41M | -5.78M | -6.57M | -11.3M | -8.08M | -6.73M | -3.97M | -5.70M | -7.02M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 5.00 | 5.00 | 5.00 | 4.00 | 0.00 | 16.00 |
| Free Cash Flow | -6.04M | -2.61M | -4.41M | -5.78M | -6.57M | -11.3M | -8.08M | -6.73M | -3.97M | -5.70M | -7.02M |
| Ratios | |||||||||||
| ROE | -6.3% | -4.3% | -13.4% | -23.2% | -32.8% | -71.1% | -87.8% | -115.6% | -235.2% | -597.6% | - |
| ROA | -6.1% | -4.2% | -13.1% | -22.2% | -31.0% | -61.4% | -71.0% | -82.7% | -58.5% | -74.0% | -91.4% |
| Net Profit Margin | -608.7% | -281.6% | -439.4% | -494.2% | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -597.6% | -215.6% |
| Debt to Equity | - | - | - | - | - | - | - | 0.02x | 2.05x | 4.11x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dyadic International Inc dividends
Dyadic International Inc has not paid dividends in the last 9 fiscal years.
Who owns Dyadic International Inc
- Insiders 22.90%
- Institutions 21.05%
- Public & others 56.06%
- Shares outstanding 40.1M
- Free float 24.1M
Top funds holding DYAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 584K | 1.46% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 125K | 0.31% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 37.6K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 37.3K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 20.6K | 0.05% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 7.39K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding DYAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 928K | 2.32% | 0.00% | Jun 2026 |
| Chapin Davis Inc | 888K | 2.22% | 0.00% | Jun 2026 |
| Apis Capital Advisors, LLC | 805K | 2.01% | -36.67% | Jun 2026 |
| BB&T Corp. | 326K | 0.81% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 251K | 0.63% | -19.97% | Jun 2026 |
| BlackRock Inc | 198K | 0.49% | -28.20% | Jun 2026 |
| Marathon Capital Management LLC | 158K | 0.39% | +43.27% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 139K | 0.35% | 0.00% | Jun 2026 |
| Sage Mountain Advisors LLC | 107K | 0.27% | 0.00% | Jun 2026 |
| HighTower Advisors, LLC | 79.5K | 0.20% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 78.8K | 0.20% | -3.53% | Jun 2026 |
| Citadel Advisors Llc | 74.3K | 0.19% | 0.00% | Jun 2026 |
| Northern Trust Corp | 69.7K | 0.17% | +112.31% | Jun 2026 |
| LANDSCAPE CAPITAL MANAGEMENT,LLC | 55.3K | 0.14% | -43.04% | Jun 2026 |
| AE Wealth Management LLC | 53.8K | 0.13% | 0.00% | Jun 2026 |
| Perkins Capital Management Inc | 48.1K | 0.12% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 46.7K | 0.12% | 0.00% | Jun 2026 |
| State Street Corp | 42.6K | 0.11% | 0.00% | Jun 2026 |
| Appleseed Capital | 41.7K | 0.10% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 41.2K | 0.10% | 0.00% | Jun 2026 |
Dyadic International Inc company profile
- Company name
- Dyadic International Inc
- Ticker
- DYAI.US
- Exchange
- USA Stocks
- Listed since
- Nov 5, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 1044 North U.S. Highway One, Jupiter, FL, United States, 33477-5094
- Phone
- 561 743 8333
- Website
- dyadic.com
About Dyadic International Inc
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Dyadic International Inc management
4- Mr. Mark A. EmalfarbFounder, CEO & Director · born 1956
- Mr. Joseph P. HazeltonPresident & COO · born 1976
- Ms. Ping Wang Rawson CPA, M.B.A.CFO & Principal Accounting Officer · born 1975
- Ms. Ana Gómez RodriguezSecretary of the Board